MetaCap

Annexon Inc. (ANNX)

NASDAQ: ANNXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.10-0.31 (-9.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANNX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$591.37M
EPS (TTM)
-$1.01
52-week range
3.07 – 7.18
Day range
3.07 – 3.37
Volume / Avg
4.45M / 3.36M
Beta
—

52-week range

$3.07$7.18

ANNX stock today

Annexon (ANNX) closed at $3.10 on Nov 20, down 9.09% (-$0.31), versus the S&P 500's 3.70% decline. Shares are 56.8% below their 52-week high of $7.18, set on Jan 23, 2026 and 1.0% above the 52-week low of $3.07, near the bottom of the past year's range. ANNX is down 38.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.4%.

Annexon has posted a net loss over the last twelve months (EPS of -$1.01), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Annexon

Company profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Douglas E. Love Esq., J.D.
Headquarters
Brisbane, CA
Employees
97
IPO year
2020

Financial highlights

Full financials

Annexon reported a net loss of $206.7 million, compared with a loss of $138.2 million a year earlier. Diluted earnings per share came in at -$1.34.

Annexon annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-206.69M$-138.20M$-134.24M$-141.95M$-130.32M
EPS (diluted)$-1.34$-1.01$-1.77$-2.60$-3.40

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$17.00+448.39%

  • Strong buy 2
  • Buy 6
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $27.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.25 vs $-0.28
Surprise
+10.71%

ANNX news

All ANNX news

Annexon peers

Health Care sector
ANNX peer companies
CompanyPrice% ChgMarket capCompare
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs ANNX
DSGNDesign Therapeutics Inc.9.02-3.22%$577.61Mvs ANNX
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs ANNX
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs ANNX
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs ANNX
GERNGeron Corporation0.8707-4.63%$560.94Mvs ANNX
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs ANNX
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs ANNX

Indexes, lists and sector

Annexon stock FAQ

What is Annexon's stock price today?

ANNX last traded at $3.10 as of Nov 20, 4:00 PM EST, down 9.09% on the day. Prices are delayed at least 15 minutes.

Who is Annexon's CEO?

Mr. Douglas E. Love Esq., J.D. is the chief executive officer of Annexon Inc., which has about 97 employees.

What is the ANNX 52-week high?

The 52-week high for ANNX is $7.18 and the 52-week low is $3.07. The stock is currently 56.8% below its high.

Compare ANNX